

### **REMARKS**

Claims 1-7, 9, 10, 20, and 22 are pending. Claims 1-4, 7, and 22 are cancelled. Claims 5, 6, 7, 9, 10 and 20 are amended. Claims 124-126 are added. The amendments find support in the specification and claims as originally filed. No new matter is added.

#### **Objection to the Title**

The Office Action states that the title of the invention is objected to as not being descriptive. Applicants have amended the title to be more descriptive of the claimed invention and request that the objection be reconsidered and withdrawn.

#### **Sequence Compliance**

The Office action states that the specification is objected to as containing sequences that are not referred to by a SEQ ID number. Applicants have amended the specification and drawings to properly identify sequences with a SEQ ID number, and request that the objection be withdrawn.

#### **Rejection of Claims 1-4, 7, 10, 20 and 22 Under 35 U.S.C. §112, First Paragraph**

The Office Action states that claims 7 and 22 are rejected under §112, first paragraph as failing to comply with the enablement requirement. The Office Action states that claim 7 recites a polypeptide comprising the amino acid sequence of SEQ ID NO: 73. The Office Action states that because SEQ ID NO: 73 is unlikely active in binding ChemerinR, the specification provides no guidance on using the polypeptide of SEQ ID NO: 73 in a binding assay. Applicants disagree and traverse the rejection.

Claims 7 and 22 have been cancelled. Applicants accordingly request that the rejection be reconsidered and withdrawn.

The Office Action states that claims 1-4, 10, and 20 are also rejected for lack of enablement. The Office Action states that the specification is enabling for a polypeptide comprising the sequence of SEQ ID NO: 61, but does not provide enablement for the genus of polypeptides comprising SEQ ID Nos 92, 93, or 94.

Claims 1-4 have been cancelled. Claims 10 and 22 have been amended to depend from claim 5, which recites a polypeptide comprising SEQ ID NO: 61. As acknowledged in the Office Action, the Specification is enabling for a polypeptide comprising SEQ ID NO: 47. Accordingly, Applicants request that the rejection be reconsidered and withdrawn.

**Rejection of claims 1-3, 10, and 20 Under 35 U.S.C. §102**

The Office Action states that claims 1-3, 10, and 20 are rejected under §102(b) as anticipated by Williams et al., and under §102(e) as anticipated by Dumas Milne Edwards et al. Applicants disagree and traverse the rejection.

Claims 1-3 have been cancelled, and claims 10 and 20 have been amended to depend from claim 5, which recited a polypeptide comprising the sequence of SEQ ID NO: 61. Thus, the teachings in Williams et al. and Dumas Milne Edwards et al. relating to a polypeptide comprising the sequence of SEQ ID NO: 92 do not anticipate the amended claims. Applicants therefore request that the rejection be reconsidered and withdrawn.

In view of the above amendment, applicant believes the pending application is in condition for allowance.

Dated: February 12, 2008

Respectfully submitted,

Electronic signature: /Matthew Beaudet/  
Matthew Beaudet

Registration No.: 50,649  
EDWARDS ANGELL PALMER & DODGE  
LLP

P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 239-0614  
Attorneys/Agents For Applicant